BRAINBox Solutions, Inc. specializes in developing and manufacturing diagnostic tests for traumatic brain injury (TBI), particularly mild traumatic brain injury. Based in Richmond, Virginia, the company employs a multi-modality approach that integrates blood biomarker panels, neurocognitive testing, and point-of-care instruments to provide objective evidence of injury and predict patient recovery. Its quantitative tests combine injury-related blood protein biomarkers with computerized neurological assessments, enhancing the accuracy of diagnoses and prognoses. Founded in 2002, BRAINBox Solutions aims to lead the industry in TBI assessment and management through innovative solutions.
SonoMotion Inc. develops non-invasive solutions for kidney stone disease. It offers Break Wave, which fragments large kidney stones; and Stone Clear that helps clear the resulting stone fragments within 15 minutes in an office setting and also without general anesthesia or X-ray radiation. SonoMotion Inc. was founded in 2012 and is based in San Mateo, California.
Kanova is a biopharmaceutical firm.
Endotronix Inc. specializes in the development of miniaturized, wireless, and implantable pressure sensors designed for interventional cardiovascular procedures. The company focuses on hemodynamic monitoring technologies that enable the early detection of worsening heart failure. Its innovative platform includes a cloud-based disease management system and an outpatient hemodynamic management solution featuring an implantable wireless pulmonary artery sensor. Founded in 2007, Endotronix is headquartered in Lisle, Illinois.
CoNextions Medical, Inc. manufactures tendon repair surgical healthcare equipment. It offers CoNextionsTR, a stainless steel and ultra-high molecular weight polyethylene implant that is designed for the surgically address tendon injuries. The company was founded in 2011 and is headquartered in Salt Lake City, Utah.
Endotronix Inc. specializes in the development of miniaturized, wireless, and implantable pressure sensors designed for interventional cardiovascular procedures. The company focuses on hemodynamic monitoring technologies that enable the early detection of worsening heart failure. Its innovative platform includes a cloud-based disease management system and an outpatient hemodynamic management solution featuring an implantable wireless pulmonary artery sensor. Founded in 2007, Endotronix is headquartered in Lisle, Illinois.
Nano-Micro Technology is a hardware company, which provides uniformly sized nano- and microspheres.
InSeal Medical Ltd. is a company based in Caesarea, Israel, specializing in the development and manufacturing of percutaneous vascular closure devices. The company’s flagship product, the InSeal intravascular closure device, is designed to effectively seal puncture sites resulting from medical procedures that utilize large bore sheaths. This innovative technology employs an internal biodegradable membrane that adheres to the vessel wall, supported by a self-expandable frame. By facilitating the closure of punctures in vessels ranging from 6 to 10 millimeters in diameter, InSeal Medical aims to enhance patient safety and improve recovery outcomes in vascular procedures. The company operates as a subsidiary of E-Pacing Inc.
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.
HydroCision develops, manufactures, and markets fluidjet based surgical tools for minimally invasive spine surgery requirements. Its products include SpineJet HydroSurgery System that is used to ablate, cut, and remove targeted tissue for spinal procedures, Spinejet, water-based technology solutions for minimally invasive spine surgery requirements, SpineJet HydroDiscectomy Systems, which are used to remove tissue without the risk of thermal energy for minimally invasive discectomy procedures, and AlloJet, systems to prepare bone allografts. The company also provides customer care services. HydroCision, Inc. was formerly known as Surgijet Corporation and changed its name to HydroCision, Inc. in November 1996. The company was founded in 1994 and is headquartered in North Billerica, Massachusetts.
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.
Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.
Cardiosolutions, Inc. designs and develops a product for mitral regurgitation problem. The company develops Mitra-Spacer, a reversible implantable device that provides a sealing surface for the leaflets of the mitral valve, thereby reducing or eliminating mitral regurgitation. It serves patients of various ages who suffer from moderate to severe mitral regurgitation, including those who are currently in congestive heart failure. Cardiosolutions, Inc. was founded in 2005 and is based in West Bridgewater, Massachusetts.
Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.
Sciona
Venture Round in 2007
Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.
Spirus Medical is a developer of advanced care medical devices for the gastrointestinal and cardiovascular markets. The company’s product portfolio includes the Endo-Ease Discovery and Dexterity Steerable Introducer.
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.
Claros Diagnostics, Inc. is creating products to move in-vitro medical diagnostic tests out of the laboratory and into the hands of physicians and patients.
Sciona provides gene-based personalized health and nutrition analysis and recommendations based on individual diet, lifestyle, and genetic profile. The company's Mycellf Program, which includes a diet and lifestyle questionnaire, makes recommendations for how individuals can make choices that benefit their long-term health. It also offers genetic testing products, which address personal wellness, fitness, and nutritional issues. The company was founded in 2000 and is headquartered in Aurora, Colorado.
Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.
Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. The company was founded in 1995 and is headquartered in Watertown, Massachusetts.
Hydra Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, develops novel drugs to treat pain, inflammation, cardiovascular and other diseases using its expertise in novel ion channels. Hydra's proprietary high throughput screening platforms enable the company to identify and develop drug candidates that address significant unmet medical needs. Hydra's ion channel drug discovery program is currently focused on channels implicated in pain, inflammation, and cardiovascular disease. Hydra's intellectual property portfolio, significant ion channel expertise, and flexible screening systems set it apart from other biopharmaceutical companies. Unlike classical sodium, calcium, or potassium voltage-gated channels Hydra's novel ion channels provide the potential to develop selective and safer ion channel drugs. Hydra has raised significant financing from blue-chip investors since its inception. This prominent group of investors includes Abingworth Ventures, Advanced Technology Ventures, Polaris Ventures, Lilly Bio Ventures, New Enterprise Associates, BioVentures Investors, Biogen Idec, Boston Medical Investors, and MedImmune Ventures.
Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.
Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.
Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.
Pintex Pharmaceuticals, Inc. is a private pharmaceutical company located in Watertown, Massachusetts, dedicated to the discovery and development of structure-based cancer therapeutics. The company primarily focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a significant role in cancer progression. Founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard, along with Nobel laureate Dr. Walter Gilbert and Dr. Janusz Sowadski, Pintex was established to leverage years of research and patented discoveries from the Salk Institute for Biological Studies and Harvard University. The company's innovative approach aims to develop novel cancer therapeutics and diagnostics rooted in advanced scientific research.
Angiolink Corporation offers EVS vascular closure system, an arterial stapling device for use in closing holes and punctures made in arteries in connection with the catheter-based surgical procedures, such as angioplasty and angiograms.
Verax Biomedical, Incorporated, a medical products company, develops rapid tests for the detection of bacterial contaminants in blood cells and tissues for transplantation and cellular therapies. It offers platelet, red cell, and cell therapy pan genera detection (PGD) tests. The company was founded in 1999 and is based in Marlborough, Massachusetts.
Pintex Pharmaceuticals, Inc. is a private pharmaceutical company located in Watertown, Massachusetts, dedicated to the discovery and development of structure-based cancer therapeutics. The company primarily focuses on the phosphate-specific proline isomerase Pin1 enzyme, which plays a significant role in cancer progression. Founded in May 1999 by Dr. Kun Ping Lu, a Pew scholar at Harvard, along with Nobel laureate Dr. Walter Gilbert and Dr. Janusz Sowadski, Pintex was established to leverage years of research and patented discoveries from the Salk Institute for Biological Studies and Harvard University. The company's innovative approach aims to develop novel cancer therapeutics and diagnostics rooted in advanced scientific research.
Provider of integrated data collection and data management solutions for clinical trials and drug safety